Immunotherapy in Upper Tract Urothelial Carcinoma

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Oct 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a type of treatment called immunotherapy in patients with advanced upper tract urothelial carcinoma (UTUC), a rare form of cancer that affects parts of the urinary system. The goal is to see how well this treatment works for people whose cancer has spread and who cannot be treated with surgery. Researchers are particularly interested in UTUC because it has unique characteristics that might influence how well immunotherapy works compared to other types of urothelial carcinoma, like bladder cancer.

To join this trial, participants need to be at least 18 years old and have been diagnosed with advanced or metastatic urothelial carcinoma. They should have already started treatment with a specific immunotherapy drug between 2016 and 2022. However, individuals with bladder or urethral cancer as the primary site, or those who do not want to take part in research, cannot participate. If you join the trial, you can expect to be closely monitored by healthcare professionals who will track your response to the treatment and any side effects you may experience. This study aims to gather important information that could help improve treatment options for patients with this rare cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 and more
• • Diagnosis of urothelial carcinoma (with or without variant histology)
• • Advanced/metastatic disease not amenable to local treatment with curative intent
• • Treatment with an anti-PD-(L)1 monoclonal antibody initiated between 2016 and 2022
• Exclusion Criteria:
• • Patient's opposition to this research
• • Urothelial carcinoma of bladder or urethral primary site
• • Non-urothelial tumor
• • Maintenance immunotherapy initiated without disease progression